Society for Neuro-Oncology Annual Meeting | Conference

Dr. Fine on Therapeutic Metabolic Targets in Brain Cancer

November 19th 2016

Optune Survival Benefit in GBM Sustained With Long-Term Data

November 19th 2016

Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.

Pembrolizumab Shows Durable Benefit for PD-L1-Positive Recurrent GBM

November 19th 2016

Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.

Krista Qualmann on the Effect of Genetic Testing on Treatment in Brain Cancer

November 19th 2016

Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM

November 19th 2016

Checkpoint Inhibitors Show Promise in Glioblastoma

November 19th 2016

Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.

Adding Ibudilast to Temozolomide Increases Apoptosis, Survival in Preclinical GBM Study

November 18th 2016

Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.

Expert Discusses Promising ABT-414 Trial Results in EGFR-Amplified, Recurrent GBM

November 18th 2016

A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.

Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer

November 18th 2016

Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.

Dr. Perry on Implications of WHO Tumor Classifications in Brain Cancer

November 18th 2016

Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.

Toca 511 Shows Promise in High-Grade Glioma

November 18th 2016

The gene for an anticancer drug was successfully transduced in high-grade gliomas, which resulted in an improvement in overall survival, according to data from a phase I trial of Toca 511.

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors

November 23rd 2015

Michael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Dr. Gilbert on Precision Medicine in Glioblastoma

November 23rd 2015

Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

Optimizing Precision Medicine Approaches in Glioblastoma

November 22nd 2015

The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an effort that poses both opportunities and challenges.

'Groundbreaking' Global Brain Cancer Trial Planned

November 22nd 2015

An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme, putting into motion a biomarker-driven approach that has been employed in other malignancies.

Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-Oncology

November 22nd 2015

Hideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

Dr. Butowski on Real-Time Imaging of Nanoliposomal Irinotecan Injection

November 22nd 2015

Nicholas A. Butowski, MD, discusses an early-stage study of convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.

Early Research Signals Potential for CAR T-Cell Therapy in EGFRvIII-Positive GBM

November 22nd 2015

A pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.

Dr. Mrugala on Extending Treatment With Temozolomide in Glioblastoma

November 21st 2015

Maciej M. Mrugala, MD, PhD, discusses a retrospective analysis looking at adding cycles of treatment with temozolomide in newly diagnosed patients with glioblastoma.

Rindopepimut Combo Continues to Show Strong OS Benefit in Relapsed GBM

November 21st 2015

Treatment with the immunotherapy rindopepimut plus bevacizumab resulted in a 47% reduction in the risk of death compared with bevacizumab and a control for patients with relapsed glioblastoma multiforme.